Abstract:Brain perineuronal nets (PNNs) are vital for neurocircuit stability and changes in their abundance and composition have been linked to Alzheimer's disease (AD) progression. In this work, we investigated age‐associated PNN changes in transgenic mice with tauopathy‐related AD neuropathology. 9‐month‐old PS19 (P301S) mice exhibited changes in PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) composition and abundance, but not the underlying CS proteoglycan (CSPG) core proteins, in association with pTau, gliosis, and neurodegeneration. In contrast, Tau4RTg2652 mice showed stable PNNs despite pTau accumulation, emphasizing the importance of neuroinflammation on PNN glycan integrity in AD. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by clinical symptoms of memory and cognitive deficiencies. Postmortem evaluation of AD brain tissue shows proteinopathy that closely associate with the progression of this dementing disorder, including the accumulation of extracellular beta amyloid (Aβ) and intracellular hyperphosphorylated tau (pTau) with neurofibrillary tangles (NFTs). Current therapies targeting Aβ have limited clinical efficacy and life‐threatening side effects and highlight the need for alternative treatments targeting pTau and other pathophysiologic mechanisms driving AD pathogenesis. The brain's extracellular matrices (ECM), particularly perineuronal nets (PNNs), play a crucial role in brain functioning and neurocircuit stability, and reorganization of these unique PNN matrices has been associated with the progression of AD and accumulation of pTau in humans. We hypothesize that AD‐associated changes in PNNs may in part be driven by the accumulation of pTau within the brain. In this work, we investigated whether the presence of pTau influenced PNN structural integrity and PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) compositional changes in two transgenic mouse models expressing tauopathy‐related AD pathology, PS19 (P301S) and Tau4RTg2652 mice. We show that PS19 mice exhibit an age‐dependent loss of hippocampal PNN CS‐GAGs, but not the underlying aggrecan core protein structures, in association with pTau accumulation, gliosis, and neurodegeneration. The loss of PNN CS‐GAGs were linked to shifts in CS‐GAG sulfation patterns to favor the neuroregenerative isomer, 2S6S‐CS. Conversely, Tau4RTg2652 mice exhibit stable PNN structures and normal CS‐GAG isomer composition despite robust pTau accumulation, suggesting a critical interaction between neuronal PNN glycan integrity and neighboring glial cell activation. Overall, our findings provide insights into the complex relationship between PNN CS‐GAGs, pTau pathology, gliosis, and neurodegeneration in mouse models of tauopathy, and offer new therapeutic insights and targets for AD treatment.

Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals

Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

GLYCATION OF TAU PROTEIN PROMOTES THE FORMATION OF FILAMENTS DURING TAU PHOSPHORYLATION

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

Dual Modification of Tau by Pseudophosphorylation and Glycation Does Not Enhance Amorphous Aggregation

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Multilayered N-Glycoproteome Profiling Reveals Highly Heterogeneous and Dysregulated Protein N-Glycosylation Related to Alzheimer’s Disease

Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease.

Multilayered N-glycoproteomics reveals impaired N-glycosylation promoting Alzheimer’s disease

Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β

Loss of DNA glycosylases improves health and cognitive function in a C. elegans model of human tauopathy

Role for Glyoxalase I in Alzheimer's Disease.

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment

O-GlcNAcylation Modulates the Self-Aggregation Ability of the Fourth Microtubule-Binding Repeat of Tau